A class of pyrazole derivatives is described for use in treating p38 kinase medicated disorders. Compounds of particular interest are defined by Formula IA
wherein R
1
, R
2
, R
3
and R
4
are as described in the specification.
HETEROCYCLIC MORPHINAN DERIVATIVES AND USE THEREOF
申请人:Purdue Pharma L.P.
公开号:US20180111934A1
公开(公告)日:2018-04-26
The application is directed to compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein R
1
, R
2
, R
3
, R
4
, and Z are defined as set forth in the specification. In certain embodiments, the invention is also directed to compounds of Formula II-VII and the pharmaceutically acceptable salts and solvates thereof. The invention is also directed to use of compounds of Formula I to VII, and the pharmaceutically acceptable salts and solvates thereof, to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the invention are especially useful for treating pain.
Tropylium-promoted Ritter reactions
作者:Son H. Doan、Mohanad A. Hussein、Thanh Vinh Nguyen
DOI:10.1039/d1cc02947a
日期:——
used to be one of the most powerful synthetic tools to functionalize alcohols and nitriles, providing valuable N-alkyl amide products. However, this reaction has not been frequently used in modern organicsynthesis due to its employment of strongly acidic and harsh reaction conditions, which often lead to complicated side reactions. Herein, we report the development of a new method using salts of the